Sugi Predict

Sugi Predict / Compounds / SCHEMBL544070

SCHEMBL544070

SCHEMBL544070

Cn1cc2c(C=O)cccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ LMNA P02545 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ PABPC1 P11940 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ IMPDH2 P12268 1/20 0.40
▸ CREBBP Q92793 3/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ THRB P10828 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15870921 0.81 CREBBP (0.34) KDM4EALDH1A1CREBBPBRD4NPC1
SCHEMBL21631725 0.79 ADORA2A (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1IMPDH2
SCHEMBL543896 0.78 SMN1; SMN2 (0.36) MEN1KMT2ALMNAKDM4EPABPC1
SCHEMBL2778053 0.78 NPC1 (0.45) MEN1KMT2ALMNAKDM4EHTT
SCHEMBL2778049 0.78 NPC1 (0.45) MEN1KMT2ALMNAKDM4EHTT
SCHEMBL543347 0.76 USP7 (0.35) CREBBPBRD4NPC1RAB9AUSP7
SCHEMBL543348 0.76 USP7 (0.35) CREBBPBRD4NPC1RAB9AUSP7
SCHEMBL28866124 0.75 PABPC1 (0.38) PABPC1ALDH1A1CREBBPBRD4TSHR
SCHEMBL543545 0.74 MTNR1A (0.37) MEN1KMT2ALMNAKDM4EHTT
SCHEMBL543544 0.74 MTNR1A (0.37) MEN1KMT2ALMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215012-A1 IKZF2 DEGRADERS AND USES THEREOF UNIV MICHIGAN (US) 2025-07-03 — — US disclosed
CN-119731179-A IKZF2 degradation agent and application thereof 密歇根大学董事会 2025-03-28 — — CN disclosed
EP-4499649-A1 IKZF2 DEGRADERS AND USES THEREOF Regents of the University of Michigan (US) 2025-02-05 — — EP disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 — — US disclosed
WO-2023183540-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-09-28 — — WO disclosed
WO-2023183540-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-09-28 — — WO disclosed
CN-115335378-A Monoacylglycerol lipase modulators 詹森药业有限公司 2022-11-11 — — CN disclosed
US-10131653-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-11-20 — — US disclosed
US-20180155333-A1 Heterocyclic Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 — — US disclosed
EP-2141150-B1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-12-11 — — EP disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 — — US disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 — — US disclosed
US-8030489-B2 Ornithine derivative ASTELLAS PHARMA INC. (JP) 2011-10-04 — — US disclosed
US-20100216803-A1 ORNITHINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-08-26 — — US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 — — US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 — — US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 — — US disclosed
CN-101687810-A Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL 2010-03-31 — — CN disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 — — EP disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155333-A1 Heterocyclic Compound HCRTR1, HCRTR2, OXTR MEN1 1775/4885KMT2A 730/4885LMNA 3554/4885
US-20100216803-A1 ORNITHINE DERIVATIVE PTGER4, OXER1, ODC1 MEN1 4728/4885KMT2A 2921/4885LMNA 4646/4885
US-20250215012-A1 IKZF2 DEGRADERS AND USES THEREOF IKZF1, IKZF2, IKZF3 MEN1 4085/4885KMT2A 444/4885LMNA 2571/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP MEN1 2100/4885KMT2A 1490/4885LMNA 1185/4885
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH MEN1 191/4885KMT2A 908/4885LMNA 339/4885
US-10131653-B2 Heterocyclic compound HCRTR1, HCRTR2, OXTR MEN1 1775/4885KMT2A 730/4885LMNA 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.